Suppr超能文献

甲基丙烯酰胺和N,N'-亚甲基双丙烯酰胺对瑞士小鼠发育毒性的评估。

Evaluation of the developmental toxicity of methacrylamide and N,N'-methylenebisacrylamide in Swiss mice.

作者信息

George J D, Price C J, Marr M C, Myers C B, Schwetz B A, Heindel J J

机构信息

Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709-2194, USA.

出版信息

Toxicol Sci. 1998 Nov;46(1):124-33. doi: 10.1006/toxs.1998.2506.

Abstract

Timed-pregnant CD-1 outbred albino Swiss mice received either methacrylamide (MAC; 0, 60, 120, or 180 mg/kg/day) or N,N'-methylenebisacrylamide (BAC; 0, 3, 10, or 30 mg/kg/day) p.o. in distilled water on gestational days (GD) 6 through 17. Maternal clinical status was monitored daily. At termination (GD 17), confirmed-pregnant females (27-30 per group, MAC; 24-25 per group, BAC) were evaluated for clinical status and gestational outcome; live fetuses were examined for external, visceral, and skeletal malformations. For MAC, no treatment-related maternal mortality was observed. Maternal body weight on GD 17, maternal weight gain during treatment and gestation, and corrected maternal weight gain were reduced at the high dose. Relative maternal food and water intake was not adversely affected; neurotoxicity was not observed. Relative maternal liver weight was increased at > or = 120 mg/kg/day; gravid uterine weight was decreased at 180 mg/kg/day. The maternal no-observed adverse effect level (NOAEL) was 60 mg/kg/day. The NOAEL for developmental toxicity was also 60 mg/kg/day. At > or = 120 mg/kg/day, mean fetal body weight was reduced. At 180 mg/kg/day, increased postimplantation death per litter was observed. Morphological development was not affected. The maternal NOAEL for BAC was 10 mg/kg/day. At 30 mg/kg/day, decreased maternal body weight on GD 17, maternal body weight change during treatment and gestation, corrected maternal body weight, and gravid uterine weight were observed. Relative maternal liver weight increased at 30 mg/kg/day. The developmental NOAEL was 3 mg/kg/day BAC. Mean fetal body weight was reduced at 30 mg/kg/day. At > or = 10 mg/kg/day, an increased incidence of fetal variations (extra rib) was observed, although fetal malformation rate was unaffected. MAC and BAC were not teratogenic to Swiss mice at the doses tested. BAC was more potent than MAC in causing adverse maternal and developmental effects.

摘要

对处于特定孕期的CD-1远交系白化瑞士小鼠,在妊娠第6天至第17天经口给予甲基丙烯酰胺(MAC;0、60、120或180毫克/千克/天)或N,N'-亚甲基双丙烯酰胺(BAC;0、3、10或30毫克/千克/天),溶剂为蒸馏水。每天监测母鼠的临床状态。在实验结束时(妊娠第17天),对确认怀孕的母鼠(MAC组每组27 - 30只;BAC组每组24 - 25只)进行临床状态和妊娠结局评估;对存活胎儿进行外观、内脏和骨骼畸形检查。对于MAC,未观察到与治疗相关的母鼠死亡。高剂量时,妊娠第17天的母鼠体重、治疗及妊娠期的母鼠体重增加量和校正后的母鼠体重增加量均降低。母鼠相对食物和水摄入量未受到不利影响;未观察到神经毒性。母鼠肝脏相对重量在剂量≥120毫克/千克/天时增加;妊娠子宫重量在180毫克/千克/天时降低。母鼠未观察到不良反应水平(NOAEL)为60毫克/千克/天。发育毒性的NOAEL也为60毫克/千克/天。在剂量≥120毫克/千克/天时,平均胎儿体重降低。在180毫克/千克/天时,观察到每窝着床后死亡增加。形态发育未受影响。BAC的母鼠NOAEL为10毫克/千克/天。在30毫克/千克/天时,观察到妊娠第17天母鼠体重降低、治疗及妊娠期母鼠体重变化、校正后的母鼠体重和妊娠子宫重量降低。母鼠肝脏相对重量在30毫克/千克/天时增加。发育NOAEL为3毫克/千克/天的BAC。在30毫克/千克/天时,平均胎儿体重降低。在剂量≥10毫克/千克/天时,观察到胎儿变异(额外肋骨)发生率增加,尽管胎儿畸形率未受影响。在所测试的剂量下,MAC和BAC对瑞士小鼠均无致畸性。BAC在引起母鼠和发育方面的不良反应上比MAC更具效力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验